Key result
Follistatin-like 1 (FSTL1) is a secreted glycoprotein involved in cardiovascular disease and inflammation, with potential as a target for cardiac regenerative therapy.
Why the study?
Clarification of mechanisms underlying cardiac regeneration and revascularization remains essential, and findings on FSTL1 emphasize its potential as a target for therapy.
Follistatin-like 1 (FSTL1) is a secreted glycoprotein that shows potential as a target for cardiac regenerative therapy in the context of acute coronary syndrome and heart failure.
FSTL1 may guide cardiac regeneration therapies; leaves open clinical translation pending mechanistic studies.
Follistatin-like 1 (FSTL1), a secreted glycoprotein, has been shown to participate in regulating developmental processes and to be involved in states of disease and injury. Spatiotemporal regulation and posttranslational modifications contribute to its specific functions and make it an intriguing candidate to study disease mechanisms and potentially develop new therapies. With cardiovascular diseases as the primary cause of death worldwide, clarification of mechanisms underlying cardiac regeneration and revascularization remains essential. Recent findings on FSTL1 in both acute coronary syndrome and heart failure emphasize its potential as a target for cardiac regenerative therapy. With this review, we aim to shed light on the role of FSTL1 specifically in cardiovascular disease and inflammation.
No takes yet. Share an insight, caveat, or question.
Peters et al. (2019) conducted a review in Cardiovascular disease and inflammation. Follistatin-like 1 (FSTL1) was evaluated. Follistatin-like 1 (FSTL1) is a secreted glycoprotein involved in cardiovascular disease and inflammation, with potential as a target for cardiac regenerative therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: